Company / Cash per Share
Neurocrine Biosciences Cash per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash per Share
$7.17
FY2025
5-year range
$2.36 / $7.17
FY2021-FY2025
Trend
+203.9%
vs FY2024
Sector context
#30 of 207
Health Care
What the data says
Cash per Share changed +204% YoY in FY2025, a notable deviation from the 9-year average annual change of +49%.
Based on SEC 10-K filings.
7.17 in FY2025 with a 5-year CAGR of +28.8%. Top quartile in the Health Care sector.
Improved from $2.60 to $7.17 over the past 2 years.
Health Care sector context is included.
Cash per Share over time
Growth rates
- 3-Year CAGR
- +37.3%
- 5-Year CAGR
- +28.8%
- 10-Year CAGR
- -
Sector benchmark
Top 14% in Health CareTop 14% of 207This company $7.17 Sector average $67.39
▼
-89.4% below sector average
Key checks
Key Insights
- In FY2025, cash per share increased 203.9% year-over-year.
- Ranks #30 out of 207 companies in the Health Care sector.
- Lowest cash per share in the period was in FY2016.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $7.17 | +203.9% |
| FY2024 | $2.36 | -9.3% |
| FY2023 | $2.60 | -6.1% |
| FY2022 | $2.77 | -24.0% |
| FY2021 | $3.64 | +79.8% |
| FY2020 | $2.03 | +63.9% |
| FY2019 | $1.24 | -22.5% |
| FY2018 | $1.60 | -45.6% |
| FY2017 | $2.93 | +203.7% |
| FY2016 | $0.97 | -0.5% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026